arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

LENZ Therapeutics, Inc.

LENZ
$5.37 ▲ +0.15 (+2.78%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
26 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

LENZ Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $168.4M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -14.1%
FCF / Share $-1.07
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.90M
↓ -84.8%
Net Income Profit after all expenses
$-41.49M
↓ -183.8%
Operating Margin Operating profit as % of sales
-151.1%
↑ +55.2% 0th
FCF / Share Free cash flow per share
$-1.07
↓ -82.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
24
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters